21 results on '"Kissick, Haydn"'
Search Results
2. Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
3. Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).
4. Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study.
5. Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
6. Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).
7. Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.
8. Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).
9. Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).
10. Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).
11. Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
12. Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).
13. Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).
14. Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).
15. Anti-PD1 (muDX 400) therapy given after radiation has greatest impact on (CD8+ Tim3- CD73+) stem cell like cells: Implications for improved clinical trial design incorporating radiation and anti-PD1.
16. Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
17. Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma.
18. Single center validation of neutrophil-to-lymphocyte ratio in localized and metastatic clear cell renal cell carcinoma.
19. Validation of a novel preoperative inflammatory score in localized, clear cell RCC.
20. Correlation between inflammatory markers in blood and expression of costimulatory molecules on tumor-infiltrating CD8+ lymphocytes in renal cell carcinoma.
21. Evaluation of major histocompatibility complex class I expression in clear cell renal cell carcinoma as a prognostic tool.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.